Europe’s drug watchdog says it has started evaluating AstraZeneca’s anti-COVID cocktail called Evusheld, which could eventually lead to the authorization of its use in the EU.
The move comes after AstraZeneca this week said trials showed that the drug, made from a combination of two monoclonal antibodies, reduced severe COVID-19 symptoms and deaths.
The decision to start the rolling review “is based on preliminary results from clinical studies, which suggest that the medicine may help protect against the disease,” the European Medicines Agency (EMA) says.
It can take several months between the start of a rolling review by the EMA and any eventual green light.
Monoclonal antibodies — which recognize a specific molecule of the target virus or bacteria — are synthetic versions of natural antibodies.